Cipro HC Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Cipro HC Availability in 2026

If you prescribe otic medications for acute otitis externa, you've likely encountered the frustration of writing a Cipro HC prescription only to have your patient call back saying their pharmacy doesn't carry it. This has been an ongoing issue for years — but significant changes in late 2025 are reshaping the availability landscape.

This briefing covers what you need to know about Cipro HC availability, the first generic approval, prescribing implications, and practical tools to help your patients access treatment efficiently.

Timeline: How We Got Here

Understanding the historical context helps frame current prescribing decisions:

• 1998: FDA approves Cipro HC Otic (Ciprofloxacin HCl 0.2%/Hydrocortisone 1% otic suspension) for acute otitis externa
• 1998-2025: Cipro HC remains a brand-only product with no generic competition for over 27 years. Market size remains relatively small — approximately $17.9 million in annual U.S. sales (IQVIA, 12 months ending September 2025)
• December 2025: FDA approves the first generic version (Cosette Pharmaceuticals), with 180 days of Competitive Generic Therapy (CGT) exclusivity
• Early 2026: Generic commercial shipments underway; pharmacy stocking gradually increasing

Prescribing Implications

Generic Availability Changes the Calculus

For years, many prescribers avoided Cipro HC in favor of more accessible alternatives (generic Ciprodex, Ofloxacin otic) due to availability and cost concerns. With the generic now available, Cipro HC becomes a more viable first-line option again for appropriate patients.

The generic is therapeutically equivalent (AB-rated) and priced at approximately $70 to $150, compared to $350-$480 for the brand — a reduction of up to 70%.

Clinical Positioning

Cipro HC remains indicated for acute otitis externa in patients ≥1 year with an intact tympanic membrane. Key prescribing considerations:

• Intact TM required: Unlike Ciprodex, Cipro HC is contraindicated in patients with perforated tympanic membranes or tympanostomy tubes
• Viral infections: Contraindicated for viral otic infections (herpes simplex, varicella)
• Dosing advantage: 3 drops BID × 7 days — simpler than Cortisporin (3-4 drops TID-QID)
• Dual action: Fluoroquinolone antibiotic + corticosteroid provides both antimicrobial coverage and anti-inflammatory benefit

When to Choose Cipro HC vs. Alternatives

• Cipro HC: Intact TM, desire for fluoroquinolone + steroid combination, patient can access generic
• Ciprodex (Ciprofloxacin/Dexamethasone): Perforated TM or tubes present, need for more potent steroid (dexamethasone > hydrocortisone), generic widely available ($30-$80)
• Ofloxacin otic: Cost-sensitive patients, perforated TM acceptable, no steroid needed, most affordable option ($15-$40)
• Cortisporin otic: Intact TM only, non-quinolone antibiotic coverage needed (neomycin/polymyxin B), generic available ($30-$80)

Current Availability Picture

As of early 2026:

• FDA shortage status: Not formally listed on the FDA Drug Shortage database
• Practical availability: Improving. Many pharmacies are beginning to stock the generic, though brand-name Cipro HC remains inconsistently available
• Supply chain: Cosette Pharmaceuticals is the sole generic manufacturer during its 180-day CGT exclusivity period. Additional manufacturers may enter after exclusivity expires (approximately mid-2026)
• Pharmacy stocking: Independent pharmacies and larger chains are increasingly carrying the generic. Specialty and compounding pharmacies remain reliable sources

Cost and Access Considerations

Understanding cost helps when discussing options with patients:

• Brand Cipro HC: $350-$480 cash price per 10 mL
• Generic (Cosette): $70-$150 per 10 mL
• With discount cards: SingleCare and GoodRx may reduce prices further
• Insurance: Coverage improving as formularies add the generic. Some plans may still require prior authorization or step therapy (typically trying ofloxacin first)
• Patient assistance: Novartis Patient Assistance Foundation (1-800-277-2254) for eligible uninsured patients

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers a provider-facing tool that helps you and your staff check real-time pharmacy stock for Cipro HC and other medications. This can save your team significant time when patients report availability issues. Instead of guessing, you can direct patients to specific pharmacies that currently have the medication in stock.

Prescribing Tips

1. Specify "generic okay" or write for the generic directly — this ensures the pharmacy fills with the more affordable and available generic
2. Consider e-prescribing with DAW-0 (Dispense as Written: substitution allowed) to facilitate generic dispensing
3. Have a backup plan ready — if Cipro HC isn't available, having Ciprodex or ofloxacin as a pre-discussed alternative reduces callbacks
4. Educate patients on the generic — some patients may not know to ask for it by its generic name (Ciprofloxacin/Hydrocortisone otic suspension)
5. Direct patients to Medfinder — medfinder.com/providers has tools to streamline the process

Patient Resources to Share

Consider sharing these resources with patients who have difficulty filling their Cipro HC prescription:

• How to Find Cipro HC in Stock Near You
• How to Save Money on Cipro HC
• Alternatives to Cipro HC

Looking Ahead

The Cipro HC market is evolving rapidly:

• Mid-2026: Cosette's 180-day CGT exclusivity is expected to expire, potentially opening the market to additional generic manufacturers
• Pricing pressure: Additional generic competition should drive prices down further, potentially bringing the generic below $70
• Formulary updates: Expect more insurance plans to add generic Cipro HC to preferred tiers as the year progresses
• Stocking improvements: As the generic becomes established, more pharmacies — including national chains — should routinely carry it

Final Thoughts

The December 2025 generic approval marks a turning point for Cipro HC accessibility. While the transition period may still present some availability challenges, the trajectory is clearly positive. For providers, the key takeaway is that Cipro HC is becoming a more practical prescribing option again — particularly when you specify the generic.

For additional provider resources, visit medfinder.com/providers. You may also find these guides useful for your practice:

• How to Help Your Patients Find Cipro HC in Stock
• How to Help Patients Save Money on Cipro HC
• What Is Cipro HC? Uses, Dosage, and What You Need to Know